Q Biomed Inc (OTCMKTS:QBIO) is a biotechnology company focused on the development, licensing and commercialization of novel molecular platforms for targeted drug delivery and immunotherapy. The company’s primary business activities center on applying proprietary technologies to enhance the effectiveness and safety of existing therapeutics and to create new treatment modalities for high‐need therapeutic areas.
The company’s core offering is its dendrimer‐based drug delivery platform, which leverages nanoscale, tree‐like polymers to improve solubility, stability and targeted tissue uptake of small molecules, biologics and nucleic acids. This platform has been applied to several pipeline candidates, including topical ophthalmic formulations and injectable treatments for oncology and central nervous system disorders, as well as nucleic acid–based therapies designed to overcome delivery barriers in gene therapy applications.
In addition to its drug delivery efforts, Q Biomed pursues cancer immunotherapy through its proprietary RhoVac platform. RhoVac is a therapeutic vaccine designed to stimulate the patient’s immune system against tumor‐associated antigens. The company has advanced preclinical and early clinical‐stage programs targeting indications such as prostate, ovarian and pancreatic cancers, often in collaboration with leading academic institutions and research hospitals to leverage specialized expertise and facilitate clinical translation.
Established in the early 2000s and headquartered in Montreal, Canada, with research and development operations in the United States, Q Biomed serves a global market through strategic partnerships, licensing agreements and contract research collaborations. The company's leadership team comprises seasoned executives with decades of combined experience in biotechnology research, regulatory affairs, clinical development and business strategy, guiding the organization’s efforts to advance its platforms and accelerate commercialization pathways.
AI Generated. May Contain Errors.
